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Cinaciguat ameliorates glomerular 
damage by reducing ERK1/2 
activity and TGF-ß expression in 
type-1 diabetic rats
Szabina Czirok1, Lilla Fang1, Tamás Radovits2, Gábor Szabó3, Gábor Szénási1, László Rosivall1, 
Béla Merkely2 & Gábor Kökény  1
Decreased soluble guanylate cyclase activity and cGMP levels in diabetic kidneys were shown to 
influence the progression of nephropathy. The regulatory effects of soluble guanylate cyclase activators 
on renal signaling pathways are still unknown, we therefore investigated the renal molecular effects of 
the soluble guanylate cyclase activator cinaciguat in type-1 diabetic (T1DM) rats. Male adult Sprague-
Dawley rats were divided into 2 groups after induction of T1DM with 60 mg/kg streptozotocin: DM, 
untreated (DM, n = 8) and 2) DM + cinaciguat (10 mg/kg per os daily, DM-Cin, n = 8). Non-diabetic 
untreated and cinaciguat treated rats served as controls (Co (n = 10) and Co-Cin (n = 10), respectively). 
Rats were treated for eight weeks, when renal functional and molecular analyses were performed. 
Cinaciguat attenuated the diabetes induced proteinuria, glomerulosclerosis and renal collagen-IV 
expression accompanied by 50% reduction of TIMP-1 expression. Cinaciguat treatment restored the 
glomerular cGMP content and soluble guanylate cyclase expression, and ameliorated the glomerular 
apoptosis (TUNEL positive cell number) and podocyte injury. These effects were accompanied by 
significantly reduced TGF-ß overexpression and ERK1/2 phosphorylation in cinaciguat treated diabetic 
kidneys. We conclude that the soluble guanylate cyclase activator cinaciguat ameliorated diabetes 
induced glomerular damage, apoptosis, podocyte injury and TIMP-1 overexpression by suppressing 
TGF-ß and ERK1/2 signaling.
The prevalence of chronic kidney disease is estimated to be 8–16% worldwide, and was ranked 18th in the list 
of causes of total number of global deaths in 20101. Diabetic nephropathy (DN) is the most common cause of 
end-stage renal disease (ESRD). Apart from cardioprotection, the renin-angiotensin-aldosterone system blockade 
is currently the most widely used therapy to slow the loss of renal function2, with additional new candidates for 
SGLT2 inhibition in diabetic patients3. However, the prevention and cure of DN is not yet solved.
DN is characterized by complex pathomechanisms including oxidative stress4, podocyte damage5 and glomer-
ulosclerosis6. The accompanying accumulation of glomerular and interstitial extracellular matrix (ECM) com-
ponents, such as collagen IV, is mostly driven by transforming growth factor-ß1 (TGF-β1) and connective tissue 
growth factor (CTGF) induced signaling pathways7. The accumulation of ECM components depends on the 
functional equilibrium of matrix metalloproteases (MMPs, which degrade the ECM), and their inhibitors (tissue 
inhibitors of metalloproteases (TIMPs)). The activation of TGF-ß signaling leads to MMP/TIMP imbalance, 
favoring fibrosis8.
The altered production of endothelial nitric oxide (NO) – through hemodynamic and paracrine effects 
between endothelial cells, podocytes and mesangial cells – and decreased glomerular cyclic 3′,5′ guanosine 
monophosphate (cGMP) levels are suggested to account for the expansive pathology in DN9, 10.
Both in vivo and in vitro studies suggest, that the NO-cGMP axis plays an important role in the mainte-
nance of renal perfusion and glomerular filtration11, apart from its antifibrotic properties (due to reduced TGF-ß 
and extracellular matrix production12–14 and inhibition of cell proliferation10). NO binds to, and activates the 
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soluble guanylate cyclase (sGC), which converts guanosine triphosphate (GTP) to cyclic guanosine monophos-
phate (cGMP), and then cGMP mediates the biological functions of NO15. Among hemodynamic actions11, 12, 
the NO–driven cGMP is important for normal podocyte function by maintaining the proper organization of slit 
diaphragm and cytoskeleton in podocytes13, 14.
Hyperglycaemia downregulates the NO-sGC-cGMP pathway and the reduced cGMP levels aggravate renal 
damage10, 16. Elevating cGMP levels by selective inhibition of the cGMP degrading phosphodiesterase-5 (PDE-5) has 
been shown to ameliorate renal disease in several animal models17–19, including both type 1 and type 2 diabetes20–22. 
Furthermore, diabetes leads to oxidative stress that can inactivate sGC through its heme prosthetic group, which 
further decreases cGMP bioavailability. The sGC activators bind to the oxidized, thus heme-free and inactive 
enzyme to increase enzyme activity, practically restoring the normal cGMP production in diseased (oxidized) 
state23. Cinaciguat (BAY 58-2667) is a potent sGC activator with a profile similar to organic nitrates/NO donors24. 
Cinaciguat has been shown to reduce renal fibrosis in both 5/6 nephrectomized25 and Dahl salt-sensitive rats26. 
However, these studies did not elucidate the molecular effects of cinaciguat on renal diseases.
Therefore, we aimed to investigate the renal molecular actions of the sGC activator cinaciguat in 
streptozotocin-induced type-1 diabetic rats, focusing on glomerular and podocyte damage, glomerular cGMP 
levels, apoptosis, cell proliferation, profibrotic signaling (TGF-ß1 CTGF, ERK1/2) and MMP/TIMP imbalance.
Results
Cinaciguat did not affect metabolic changes, renal hypertrophy or blood pressure. At the end of 
the study, diabetic rats had significantly elevated blood glucose levels and glucosuria, regardless of the treatment. 
The daily water intake rose markedly in all diabetic rats, but the cinaciguat-treated animals drank less than the 
non-treated rats (Table 1). Body weight decreased in all diabetic rats, and significant renal hypertrophy developed 
in both the DM and DM-Cin groups as shown by increased kidney weight/body weight ratio (Table 1). Compared 
to non-diabetic control groups, both DM and DM-Cin rats had lower mean arterial blood pressure (Table 1).
Cinaciguat increased serum cGMP level, urinary cGMP excretion and glomerular cGMP content 
in diabetic rats. Effectiveness of cinaciguat treatment was evaluated by serum cGMP levels at harvest. In 
non-diabetic control animals, cinaciguat did not alter plasma or urine cGMP levels. In contrast, both plasma 
cGMP level and urinary cGMP excretion was significantly elevated in DM-Cin rats (Fig. 1a,b). Double immu-
nofluorescence depicted glomerular co-localization of synaptopodin and cGMP (Fig. 1c). Similar to urine and 
plasma cGMP levels, both control groups had similar glomerular cGMP content. However, glomerular cGMP 
content was reduced in DM kidneys, in contrast to urine and plasma levels. Cinaciguat preserved glomerular 
cGMP content, in parallel with the increased plasma and urine cGMP levels (Fig. 1c).
Cinaciguat reduced diabetic glomerulosclerosis, proteinuria and TGF-ß overexpres-
sion. Compared to the control groups, the kidneys of untreated diabetic rats showed glomerular hypertrophy, 
mild mesangial expansion and tuft adhesions to Bowman’s capsule, the typical glomerular alterations in diabe-
tes (Fig. 2a–c). Additionally, tubular dilatation and atrophy were the most prominent tubulointerstitial changes 
observed in untreated DM kidneys. These alterations were accompanied by marked proteinuria, as shown by the 
increased urinary protein/creatinine ratio of diabetic rats (Fig. 2d,e). However, cinaciguat treatment of diabetic 
animals significantly reduced both glomerular and tubulointerstitial changes, as well as the extent of proteinuria 
(Fig. 2a–e).
Collagen IV immunoreactivity, as a marker of fibrosis, was markedly augmented in DM rats, but cinaciguat 
treated rats demonstrated significantly less collagen IV staining in both glomeruli and the interstitium (Fig. 3a).
The mRNA and protein expression of the profibrotic TGF-β1 was significantly elevated in the kidneys of 
untreated DM rats as compared to controls. Cinaciguat had no effect on TGF-β1 mRNA and protein expression 
in controls but it reduced TGF-β1 expression by at least 50% in diabetic rats (Fig. 3b). Accordingly, we observed 
reduced glomerular TGF-ß1 immunostaining in DM-Cin rats (Supplementary Figure 1). Moreover, cinaciguat 
was able to restore CTGF mRNA overexpression in diabetic kidneys (Fig. 3c).
Extracellular signal regulated kinases are members of the mitogen activated protein kinase (MAPK) family, 
which also plays an important role in fibrosis. Kidneys of untreated diabetic rats showed a 2-fold increase in 
ERK(1/2) phosphorylation, which was reduced to control levels by cinaciguat treatment (Fig. 3d).
Parameter Co Co-Cin DM DM-Cin Pdiabetes Ptreatment Pinteraction
Blood glucose 
(mmol l−1) 5.7 ± 0.4 6.1 ± 0.2 30.2 ± 1.6
a,b 30.3 ± 3.5a,b <0.001 0.698 0.748
Daily water intake 
(ml day−1) 33.4 ± 2.4 37.9 ± 2.6 239.8 ± 14.2
a,b 154.9 ± 15.7a,b,c <0.001 <0.001 <0.001
Body weight (g) 480 ± 60 478 ± 72 280 ± 27a,b 254 ± 46a,b <0.001 0.530 0.351
Kidney weight/body 
weight (mg g−1) 2.5 ± 0.4 2.6 ± 0.3 5.6 ± 0.4
a,b 5.9 ± 0.6a,b <0.001 0.265 0.305
Mean arterial blood 
pressure (mmHg) 79.6 ± 6.8 80.1 ± 12.1 63.7 ± 8.5
a,b 64.4 ± 9.8a,b <0.001 0.845 0.969
Table 1. Blood and urinary glucose levels, daily water intake, body weights and relative kidney weights of the 
study groups. Values are presented as mean ± SD (n = 10–12/group). ap < 0.05 vs. Co; bp < 0.05 vs. Co-Cin; 
cp < 0.05 vs. DM (two-way ANOVA with Sidak’s multiple comparisons test).
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Figure 1. Effect of diabetes and cinaciguat treatment on cyclic guanosine monophosphate (cGMP) levels in the 
plasma and urine, and glomerular cGMP content. (a) Plasma cGMP levels of DM rats were similar to Co and 
Co-Cin controls, but DM-Cin rats had significantly higher circulating cGMP levels. (b) According to plasma 
cGMP, urinary cGMP excretion increased significantly in DM-Cin rats, as compared to DM or to both controls. 
(c) Double immunostaining for synaptopodin (green) and cGMP (red) depicted visible glomerular cGMP 
content in both Co and Co-Cin kidneys, mainly co-localized with synaptopodin (yellow). Immunoreactivity 
for cGMP was practically absent in glomeruli of DM rats, but it was restored in DM-Cin kidneys. Data are 
presented as mean ± SD (n = 8–10/group). *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA with Sidak’s 
multiple comparison test).
www.nature.com/scientificreports/
4SCIentIfIC RePoRTS | 7: 11218  | DOI:10.1038/s41598-017-10125-3
Cinaciguat attenuated diabetes-related kidney remodeling. Analysis of matrix metalloproteases 
(MMPs) and their tissue inhibitors (TIMPs) revealed an imbalance between extracellular matrix production 
and degradation in diabetic kidneys, since the mRNA expression of both MMP-9 and MMP-2 were reduced 
(Fig. 4a,b). TIMP-1, the main inhibitor of MMP-9, showed a 4-fold overexpression in untreated diabetic kidneys 
as compared to controls, while renal TIMP-2 expression was repressed in both the diabetic groups. Cinaciguat 
was able to restore MMP-2 expression to control levels, but had no effect on MMP-9 expression. In contrast, 
cinaciguat ameliorated diabetic TIMP-1 overexpression without affecting TIMP-2 (Fig. 4a,b). The 92 kD gelati-
nase activity supported these results, showing significantly reduced 92 kD (MMP-9) activity in DM kidneys, but 
almost normal activity in DM-Cin kidneys. Interestingly, the 62 kD gelatinase (MMP-2) zymography did not 
reveal significant changes, although DM samples tended to have less MMP-2 activity.
Cinaciguat reduced podocyte damage, cell proliferation and apoptosis in diabetic glomer-
uli. Damaged podocytes show positive immunostaining for the intermedier filament desmin27–29. Strong glo-
merular desmin positivity was seen in the DM group as, as a marker of podocyte damage (Fig. 5a). Cinaciguat 
significantly attenuated desmin overexpression in podocytes of diabetic rats without any effect in controls 
(Fig. 5a). Nephrin and podocin mRNA expression (as further markers a podocyte injury30, 31) was reduced by 
50% in untreated diabetic animals, but they were attenuated by cinaciguat treatment (Fig. 5b).
Kidneys of untreated diabetic rats demonstrated increased rate of glomerular cell proliferation and apoptosis, 
as shown by Ki-67 immunostaining and TUNEL assay, respectively. Diabetes markedly increased the number of 
TUNEL positive tubulus cells as well. Cinaciguat treatment reduced the rate of both glomerular cell proliferation 
and apoptosis, and the number of tubular apoptotic cells in diabetic animals, but had had no effect on controls 
(Fig. 5c,d).
Figure 2. Effect of cinaciguat on kidney histology and proteinuria in diabetic rats. (a,b) Representative 
photomicrographs of PAS stained kidneys (400x magnification) show normal glomerular structure in both Co 
and Co-Cin controls, mesangial expansion and glomerular hypertrophy in DM and almost normal structure 
in DM-Cin groups (scale bar represents 50 μm). (c,d) Glomerular and tubulointerstitial damage index scores 
of each group are shown. (e) The extent of proteinuria was determined by urinary protein/creatinine ratio (mg 
protein/mg creatinine), showing significant proteinuria in DM that was reduced in DM-Cin rats. Data are 
presented as mean ± SD (n = 8–10/group). **p < 0.01, ***p < 0.001 (two-way ANOVA with Sidak’s multiple 
comparison test).
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Cinaciguat attenuated the diabetes induced disruption of renal NO-sGC-cGMP-PKG signal-
ing. Immunoblot analysis confirmed the diabetes related impairment of the NO-sGC-cGMP-PKG axis. First, 
the renal expression of PDE-5 was increased by 5-fold in untreated diabetic rats (Fig. 6a), and immunostaining 
depicted a marked glomerular PDE-5 overexpression with significant co-localization with podocyte marker syn-
aptopodin (Fig. 6b). This was accompanied by 50% reduction in sGCß1 protein expression both in the glomeruli 
Figure 3. Effect of diabetes and cinaciguat on renal fibrosis. (a) Immunostaining for collagen IV was performed 
on paraffin embedded kidney sections. Representative photomicrographs (200x magnification) show moderate 
tubulointerstitial and glomerular staining in controls, strong tubulointerstitial and thickened glomerular 
expression in DM but only mild collagen IV expression in DM-Cin groups (scale bar represents 50 μm).  
(b,c) Compared to controls, the renal mRNA and protein expression analysis of profibrotic TGF-ß as well as 
CTGF mRNA expression showed a marked overexpression in DM kidneys, which was significantly attenuated 
in DM-Cin group. TGF-ß protein expression of each sample was normalized for tubulin expression and given 
as fold change relative to a calibrator. The mRNA expression were normalized for GAPDH expression using 
the formula 2−ΔΔCt. (d) DM kidneys showed significantly increased phosphorylation of the p44/p42 MAPK 
(ERK1/2) as compared to non-diabetic controls, which was inhibited by cinaciguat treatment, as seen in DM-
Cin kidneys. Representative immunoblots are shown. Phospho-ERK1/2 expression was normalized for total 
ERK1/2 expression of each sample and given as fold change. Data are presented as mean ± SD (n = 8–10/group). 
**p < 0.01, ***p < 0.001 (two-way ANOVA with Sidak’s multiple comparison test).
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Figure 4. Effect of cinaciguat on the expression of renal extracellular matrix turnover components. (a) 
Compared to the non-diabetic controls, MMP-9 mRNA expression was markedly reduced in DM kidneys, 
accompanied by 4-fold increased TIMP-1 expression. Although cinaciguat did not alter MMP-9 expression, it 
attenuated TIMP-1 overexpression, which resulted in slightly better MMP-9/TIMP-1 ratio in DM-Cin kidneys, 
as compared to DM, supported by the MMP-9 zymography results. (b) The renal mRNA expression of MMP-2 
dropped in DM rats, but was normalized in DM-Cin group. TIMP-2 mRNA expression reduced in both DM 
and DM-Cin groups, but the MMP-2/TIMP-2 imbalance was attenuated in DM-Cin kidneys. Zymography 
did not show, in contrast, significant changes in MMP-2 activity. Representative zymogram bands are shown. 
The mRNA expression was normalized for GAPDH expression using the formula 2−ΔΔCt. Data are presented 
as mean ± SD (n = 8–10/group). *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA with Sidak’s multiple 
comparison test).
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Figure 5. Evaluation of podocyte damage, glomerular cell proliferation and apoptosis. (a) Immunostaining for 
desmin, as marker of podocyte damage, was performed on paraffin embedded kidney sections. Representative 
photomicrographs (400x magnification) show no staining in non-diabetic controls, but several positive podocytes 
(arrows) in DM with significantly reduced staining intensity in DM-Cin kidneys (scale bar represents 50 μm). 
(b) Compared to controls, the mRNA expression of nephrin and podocin was reduced by at least 40% in DM 
kidneys, showing diabetic podocyte damage. Both nephrin and podocin expression was significantly ameliorated 
in DM-Cin kidneys. The mRNA expression was normalized for GAPDH expression using the formula 2−ΔΔCt. (c) 
Representative photomicrographs for Ki-67 are shown (400x magnification), as a marker of cell proliferation. We 
detected significantly more Ki-67 positive proliferating glomerular cells in DM rats than in non-diabetic controls, 
which difference was abolished by cinaciguat treatment. (d) TUNEL assay demonstrated a marked increase of 
apoptotic glomerular and tubular cell count in DM rats vs. controls, which was significantly reduced in DM-Cin 
kidneys. Scale bar represents 50 μm. Data are presented as mean ± SD (n = 8–10/group). *p < 0.05, **p < 0.01, 
***p < 0.001 (two-way ANOVA with Sidak’s multiple comparison test).
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Figure 6. Analyses of renal PDE-5 protein expression and glomerular immunoreactivity. (a) As compared 
to non-diabetic controls, DM kidneys showed 6-fold increased PDE-5 expression. Cinaciguat treatment only 
tended to lower PDE-5 expression in DM-Cin kidneys. (b) Double immunostaining with the podocyte marker 
synaptopodin (green) revealed minimal basal PDE-5 expression (red) in controls but strong glomerular 
co-localization in DM and DM-Cin kidneys (yellow color). Bar represents 50 μm (400x magnification). 
Representative PDE-5 immunoblot is shown. Protein expressions were normalized to tubulin and expressed 
as fold change relative to a calibrator control sample. Data are presented as mean ± SD (n = 8–10/group). 
**p < 0.01 (two-way ANOVA with Sidak’s multiple comparison test).
www.nature.com/scientificreports/
9SCIentIfIC RePoRTS | 7: 11218  | DOI:10.1038/s41598-017-10125-3
Figure 7. Immunoblot analysis of the renal NO-cGMP pathway components. (a,b) Glomerular and tubular 
guanylate cyclase (sGCβ1) immunohistochemistry depicted strong glomerular and tubular staining in non-
diabetic controls (arrows), with 40% reduction of expression both in total kidney homogenates (a) and in 
glomeruli and tubuli of DM rats (b). Both glomerular and tubular sGC staining was significantly stronger 
in DM-Cin kidneys, as compared to DM. (c,d) As compared to non-diabetic controls, DM kidneys showed 
significant PKG overexpression (c) and increased number of positive glomerular cells (d). Cinaciguat treatment 
ameliorated PKG overexpression in DM-Cin as shown by immunblot (c) and immunostaining (d). Bar 
represents 50 μm (400x magnification). Representative immunoblots are shown. All protein expressions were 
normalized to tubulin and expressed as fold change relative to a calibrator control sample. Data are presented 
as mean ± SD (n = 8–10/group). *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA with Sidak’s multiple 
comparison test).
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and the tubuli (Fig. 7a,b) and a significant PKG overexpression (Fig. 7c,d). Cinaciguat markedly reduced the renal 
PKG overexpression, and restored sGCß1 expression to control levels in DM-Cin rats (Fig. 7a–d).
Discussion
The present study demonstrates that sGC activation by cinaciguat restored the glomerular cGMP content, 
reduced TGF-ß1 expression and ERK1/2 phosphorylation attenuating podocyte injury, proteinuria, glomerular 
cell proliferation and apoptosis in the rat model of type-1 diabetes. Furthermore, cinaciguat restored the renal 
MMP/TIMP imbalance and reduced the hyperglycemia-induced extracellular matrix accumulation.
Although many aspects of the pathomechanisms are still unclear, the NO-cGMP pathway impairment plays an 
important role in diabetic nephropathy. First, less NO is produced32, and more NO is scavenged due to increased 
production of superoxide. Second, the progressive inhibition and downregulation of sGC33 decreases cGMP 
production. The increased activity of the cGMP-degrading PDE-5 due to hyperglycemia further decreases the 
bioavailability of cGMP21, 22. Decreased cGMP levels results in reduced activity of the cGMP-dependent protein 
kinase type I (PKG), which might contribute to renal fibrosis34, 35. These findings were confirmed in our study 
by reduced glomerular cGMP content in diabetic rats, accompanied by podocyte damage and proteinuria. The 
NO-cGMP-sGC-PKG pathway impairment was further indicated by the glomerular PDE-5 overexpression, cor-
roborating previous findings21, 22, accompanied by reduced sGC protein expression in diabetic kidneys. Despite of 
the increased PKG protein expression, the reduced renal cGMP bioavailability resulted in significantly increased 
glomerular TGF-β expression, podocyte damage (represented by elevated desmin but reduced nephrin and podo-
cin expressions), glomerular apoptosis (as shown by TUNEL staining) and a modest increase in proliferating 
glomerular cell number. Despite the cGMP signaling impairment, the serum and urinary cGMP levels were not 
significantly reduced in DM rats as compared to controls, confirming our previous observations22, 36. This finding 
can be a consequence of diabetes-related increase in atrial natriuretic factor expression, which can activate the 
particulate guanylate cyclase (pGC) in other organs, resulting in a compensatory overflow of cGMP from these 
tissues into the plasma37.
In order to increase cGMP production, several sGC stimulators and sGC activators have been developed. 
Stimulators act synergistically with NO on the reduced sGC enzyme. In contrast, sGC activators bind only to 
the oxidized (therefore inactive) sGC enzyme, an advantage over stimulators in the treatment of diseases with 
oxidative stress38. Accumulating evidence suggests that both sGC stimulators39 and sGC activators might exert 
antifibrotic effects. Boustany-Kari and collegues recently reported that a sGC activator compound attenuated pro-
teinuria and renal fibrosis on a type-2 DM rat model40, although the molecular background was not elucidated.
Cinaciguat preferentially activates the oxidized (inactive) enzyme23, 24 and has cardioprotective effects in dia-
betes36. Cinaciguat was reported to delay renal fibrosis in 5/6 nephrectomized25 and in Dahl salt-sensitive rats26. 
However, the regulatory effects of sGC activators on renal profibrotic signaling pathways (eg. TGF-ß1 or MAP 
kinases) or MMP/TIMP imbalances have not been investigated yet. Diabetes leads to glomerular and intersti-
tial extracellular matrix (ECM) accumulation, such as collagen IV, mostly driven by TGF-β1-induced signaling 
pathways7. Hyperglycaemia induces TGF-β1 production in mesangial cells41. In our study, cinaciguat attenuated 
mesangial expansion and glomerular TGF-β1 expression. Apart from direct transcriptional activation of ECM 
proteins by TGF-β, the ECM accumulation highly depends on the balance of matrix degrading MMPs and their 
inhibitors (TIMPs). In our study, diabetes markedly increased TIMP-1 expression and reduced MMP-9/TIMP-1 
ratio, leading to reduced MMP-9 gelatinase activity. TGF-β can induce TIMP-1 expression through both the Smad 
signaling8 and the activator protein 1 (AP-1) pathway42. Extracellular-regulated protein kinase 1/2 (ERK1/2) is 
an important player in the intracellular signal transduction system, which is involved in cell proliferation and 
extracellular matrix protein synthesis, partly mediated by AP-143. TGF-β activates ERK1/2 in mesangial cells44 
while ERK1/2 mediates TGF-β-induced matrix accumulation45 and ERK1/2 inhibition reduces TGF-β-induced 
collagen synthesis46. Hyperglycemia further promote ERK1/2 phosphorylation and subsequent upregulation of 
ECM components in diabetes47.
Both TGF-β, and ERK1/2 activation leads to increased AP-1 activity43. As AP-1 can induce TIMP-142, the 
increased ERK1/2 phosphorylation and TGF-β expression explains the TIMP-1 overexpression and the progres-
sive matrix accumulation in our untreated diabetic rats. Cinaciguat, by activating oxidized sGC and elevating 
cGMP levels, attenuated both renal ERK1/2 phosphorylation and TGF-β expression in diabetic kidneys. As a lim-
itation, however, we could not investigate ERK1/2 phosphorylation of specific glomerular cells, only of the whole 
kidney. The recently reported sGC-TGFβ-ERK1/2 pathway crosstalk explains our observations48 that cinaciguat 
significantly reduced collagen-IV production and TIMP-1 expression.
Podocyte injury plays a major role in the pathogenesis of diabetic glomerular damage5, 49. High glucose 
increases podocyte sensitivity to ambient TGF-β150 and stimulates mesangial TGF-β1 expression5, while TGF-β1 
overproduction by mesangial cells41, 50 induces further podocyte damage, causing effacement51 and apoptosis52. 
Reduced cGMP levels might also result in hyperglycemia-induced TGF-β activation in the mesangium53. In our 
study, decreased glomerular cGMP content (including podocytes) might have contributed to cytoskeletal rear-
rangement in injured podocytes that caused filtration barrier leakage13, 14 and consequent proteinuria54, 55. This 
was evidenced by reduced expression of nephrin and podocin5, 49, the major components of the slit diaphragm 
between foot processes. In our study, DM reduced both tubular and glomerular sGC immunoreactivity, which 
was attenuated by cinaciguat treatment. In the glomerulus, sGC plays an important role both in mesangial cells56 
and podocytes57. We suggest that the activation of oxidized sGC in podocytes and mesangial cells attenuated 
podocyte damage and restored nephrin and podocin expression by increasing intracellular cGMP levels in dia-
betic glomeruli, as shown by cGMP immunostaining. Additionally, the elevated circulating cGMP levels observed 
in cinaciguat treated diabetic rats might further reduce the glomerular activation of latent TGF-β1, as supported 
by reduced glomerular TGF-β1 immunostaining34.
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One should also consider that elevated serum cGMP levels might result in blood pressure effects that conse-
quently can alter renal damage. The sGC stimulator riociguat has been shown to reduce blood pressure and renal 
fibrosis in models of hypertension39. In our study, however, both diabetic groups had significantly lower MAP, 
which was not affected by cinaciguat. As both diabetic groups exhibited significant glucosuria, we presume that 
the osmotic polyuria might be responsible for the lower MAP58. We also have to consider the metabolic acidosis 
which could influence renal function, as insulin supplementation was not used in our study59. However, both 
diabetic groups had comparable weight loss and blood glucose levels, which indicates that cinaciguat had no 
effect on metabolic parameters. Nevertheless, we propose that the beneficial effects of cinaciguat treatment were 
independent of blood pressure or ketoacidosis in our study.
In terms of clinical translation, another limitation of our study is that diabetic rats did not develop hyper-
tension or severe glomerulosclerosis. These are common clinical features of diabetic nephropathy patients and 
give rationale for combination treatments including RAS blockade. In a combined hypertensive-diabetic mouse 
model, the sGC stimulator riociguat has been shown to improve nephropathy on top of RAS blockade60. In the 
present study, our major goal was to elucidate the specific renal action of cinaciguat in monotherapy. Further 
animal studies are needed to investigate the possible additive therapeutic potential of sGC activator cinaciguat in 
combination with RAS blockade.
Conclusions
In our study on the rat model of T1DM, the NO-independent chronic activation of sGC by cinaciguat effectively 
restores glomerular cGMP levels, and attenuates diabetic podocyte damage, glomerular apoptosis and fibrosis 
through suppression of TGF-ß overproduction and ERK1/2 phosphorylation. To the best of our knowledge, this 
is the first in vivo study showing the blood pressure independent renal molecular effects of chronic cinaciguat 
treatment in diabetes. Our observation and previous reports suggest the possible use of cinaciguat as a new regi-
men in the treatment of DN.
Methods
Animals. Male Sprague-Dawley rats (250–300 g, Charles River, Sulzfeld, Germany) were housed at a constant 
temperature of 22 ± 2 °C with 12 h light/dark cycles, had access to standard rodent chow and water ad libitum.
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH Publication No. 85–23, revised 1996). All procedures and handling of animals 
during the investigations were reviewed and approved by the institutional and national ethical committees for 
animal experimentation (permission number: 22.1/1162/3/2010).
Induction of diabetes mellitus. Type 1 diabetes mellitus was induced with a single intraperitoneal 
dose of freshly dissolved streptozotocin (STZ, 60 mg/kg) in 0.1 mol/L citrate buffer. Control animals received 
buffer only. After 72 h, blood glucose concentration was determined using a digital blood glucose meter and 
test strips (Accu-Chek® Sensor, Roche Inc., Mannheim, Germany). Only animals with random blood glucose 
level > 15 mmol/l were considered diabetic and were included in the study.
Experimental groups, treatment protocol. Diabetic rats were randomized to diabetic control (DM, 
n = 8) and cinaciguat treatment (DM-Cin, n = 8) groups. Rats injected only with citrate buffer instead of strep-
tozotocin served as non-diabetic controls (Co, n = 10) plus there was an additional non-diabetic control group 
with cinaciguat treatment (Co-Cin, n = 10). The rats were treated for 8 weeks with the soluble guanylate cyclase 
activator, cinaciguat (Co-Cin and DM-Cin group, 10 mg kg−1 day−1 suspended in 0.5% methylcellulose solution 
or with vehicle (Co and DM groups) per os via oral gavage. Water bottles were filled every morning with the same 
amount of fresh tap water and daily water intake was measured. Body and kidney weights were measured at the 
time of harvest.
Blood pressure measurements, blood and urine chemistries. At the end of the treatment period, 
rats were anesthetized with i.p. ketamine (100 mg/kg) and xylazine (3 mg/kg) and were placed on controlled 
heating pads. Arterial blood pressure was recorded by 2 F microtip pressure-volume catheter (SPR-838, Millar 
Instruments, Houston, TX, USA), and mean arterial pressure (MAP) was computed.
Blood samples were taken from the inferior caval vein. Urine samples were obtained by sterile puncture of the 
urinary bladder. Serum glucose levels as well as urine creatinine concentration were determined photometrically 
on a Reflotron analyzer (Roche, Boehringer-Mannheim, Mannheim, Germany). Urine protein concentration 
was measured using the BCA Protein Assay (Pierce Thermo Scientific, Rockford, USA), and urinary protein/
creatinine ratios were calculated.
Plasma and urine levels of cyclic guanosine monophosphate (cGMP) were determined by enzyme immuno-
assay (EIA) using a commercial kit (Amersham cGMP EIA Biotrak System, GE Healthcare, Buckinghamshire, 
UK). Plasma cGMP concentration was evaluated as µmol/ml. Urine cGMP concentration (pmol/ml) was normal-
ized for creatinine (mg/ml) and urinary cGMP excretion was calculated as pmol cGMP/mg creatinine.
Renal histology, immunohistochemistry and TUNEL staining. Periodic-acid Schiff (PAS) staining 
was performed on formalin fixed, paraffin embedded kidney samples to assess glomerular and tubular damage22. 
The glomerular score of each animal was derived as the arithmetic mean of 60 glomeruli (400x magnification). 
The tubulointerstitial damage index (dilatation, atrophy, hyaline in tubular lumen, visible detachment of tubular 
cells, interstitial infiltration of mononuclear cells and interstitial fibrosis) was assessed as previously described22. 
Additionally, the average area of 30 glomeruli per kidney sections in 4 samples per group were calculated with 
ImageJ software61.
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Immunohistochemistry was performed on paraffin sections, using the avidin-biotin method, as previously 
described22. Citrate buffer pH 6.0 was used for antigen retrieval, and slides were incubated with primary anti-
bodies overnight at 4 °C (rabbit polyclonal anti-collagen IV, 1:1000, AbD Serotec, Bio-Rad, Puchheim, Germany; 
mouse monoclonal anti-desmin, 1:50, Dako Cytomation, Frank Diagnosztika, Budapest, Hungary; rabbit pol-
yclonal anti-sGCß1 1:500, Novus Biologicals, Littleton, CO, USA; rabbit polyclonal anti-PKGI 1:100, Enzo, 
Farmingdale, NY, USA; rabbit monoclonal anti-Ki-67 1:1000, Abcam, Cambridge, UK) then with appropriate 
secondary antibodies (BioGenex, San Ramon, CA, USA) for 30 min and developed using Fast Red (Dako).
In order to detect DNA strand breaks as marker of apoptosis, terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL) assay was performed using a commercial kit (DeadEnd Colorimetric TUNEL System, 
Promega, Mannheim, Germany) on paraffin embedded kidney sections, according to the manufacturer’s protocol.
Immunohistochemical and TUNEL assays were evaluated in a blinded manner. Reactivity of glomerular 
desmin (400x magnification), Ki-67 and TUNEL staining were evaluated by counting positive cells per glomeru-
lus in each field of the section, and the average of positive cells/glomerulus per specimen was calculated. Tubular 
TUNEL reactivity was assessed at 200x magnification as an average of positive cells per field. Collagen IV and 
sGCß1 staining were quantified as follows: intensity score (1 = weak staining, 2 = intermediate staining, 3 = exten-
sive staining) and area score (1 = up to 10% positive cells, 2 = 11–50% positive cells, 3 = 51–80% positive cells, 
4: > 80% positive cells) was assessed, and an average score was calculated for each field of view (intensity score 
multiplied by area score).
Cyclic GMP and synaptopodin, as well as PDE-5 and synaptopodin double immunostaining were performed 
on frozen kidney sections. Briefly, sections were fixed with 4% paraformaldehyde for cGMP or ice-cold acetone 
for PDE-5, then rehydrated with PBS, blocked using 5% donkey serum, and then incubated with primary anti-
bodies (rabbit polyclonal anti-cGMP, 1:1000, Abcam, or rabbit polyclonal anti-PDE-5a, 1:200, Enzo, and mouse 
monoclonal anti-synaptopodin, 1:500, Fitzgerald Industries, Acton, MA, USA), followed by secondary antibod-
ies (Dylight-488 conjugated donkey anti-mouse and Cy3 conjugated donkey anti-rabbit, both at 1:500, Jackson 
Immunoresearch, West Grove, PA, USA), and then washed, mounted and analyzed under fluorescent microscope.
TGF-ß and nephrin double staining was performed similarly, using mouse monoclonal anti-TGFß (1:200, 
R&D Systems, Minneapolis, MN, USA) with guinea pig polyclonal anti-nephrin (1:200, Fitzgerald Industries) as 
primary antibodies, and Cy3-comjugated donkey anti-mouse and Dylight488 conjugated anti-guinea pig (both 
at 1:200, Jackson Immunoresearch) as secondary antibodies.
Immunoblot. Kidney samples (20 mg) were homogenized in RIPA lysis buffer containing complete protease 
inhibitor cocktail (Roche). Protein concentration was determined by the BCA Assay. Samples were mixed with 
2x Laemmli buffer and boiled. Equal amounts of protein (40 µg) were separated on 10% SDS-polyacrylamide 
gel, transferred to nitrocellulose membranes and blocked with 5% skim milk in Tris-buffered saline (TBS), 
containing 0.1% Tween-20. Membranes were incubated overnight at 4 °C with primary antibodies (rabbit poly-
clonal anti-TGF-β1 antibody 1:500, SantaCruz Biotechnology, Santa Cruz, CA, USA; rabbit polyclonal anti-PKG 
1:2000, Enzo, Farmingdale, NY, USA; rabbit polyclonal anti-sGCß1 1:2000, Novus Biologicals; rabbit polyclonal 
anti-PDE5a 1:1000, Enzo; p44/42 MAPK (ERK1/2) and phospho-p44/42 MAPK (pERK1/2) (Thr202/Tyr204) 
both at 1:1000, Cell Signaling, Danvers, MA, USA), then washed and incubated with peroxidase-conjugated sec-
ondary antibody (anti-mouse IgG or anti-rabbit IgG, 1:2000, Cell Signaling). Blots were visualized by ECL detec-
tion kit (Pierce Thermo). Original immunoblots are shown in Supplementary Figure 2 for PDE-5, TGF-ß1 and 
p-ERK and in Supplementary Figure 3 for PKG and sGCß1.
Gelatin zymography. MMP-2 and MMP-9 activity was estimated by gelatin zymography. Kidneys were 
homogenized in lysis buffer (50 mM TRIS-HCl pH 7.5; 500 mM NaCl; 5 mM CaCl2) containing EDTA-free com-
plete protease inhibitor cocktail (Roche, Indianapolis, IN, USA) and protein concentration was determined using 
the BCA Protein Assay Kit (Pierce Thermo Scientific). Equal quantities (40 µg) of protein were loaded in 8% 
polyacrylamide gels containing 0.1% gelatin, and electrophoresis was performed under non-reducing conditions. 
Following electrophoresis, gels were washed with 2.5% Triton X-100 for 20 min to remove sodium dodecyl sulfate. 
Gels were incubated at 37 °C for 18 h (for MMP-2) or 24 h (for MMP-9) in renaturing buffer (50 mM TRIS-HCl; 5 
Mm CaCl2; 1 µM ZnCl2; 0.02% NaN3), washed in fixing buffer (30% methanol, 10% acetic acid), and stained with 
0.5% (w/v) Coomassie Blue R-250 (Biomol, Hamburg, Germany) in fixing buffer for 30 min at room temperature. 
Gels were destained with fixing buffer. Gelatinolytic activity was visualized as a clear band in a blue background. 
Band intensity was quantified using ImageJ61. Original zymogram is shown in Supplementary Figure 4.
Quantitative RT-PCR. 50 mg of whole kidneys were homogenized and total RNA was isolated according to 
the manufacturer’s protocol (TRIzol, Thermo Fisher Scientific, Waltham, MA, USA). 2 μg RNA was reverse tran-
scribed (High Capacity cDNA Reverse Transcription kit, Thermo) using random primers. PCR reactions were 
performed on a BioRad CFX thermal cycler (BioRad, Hercules, CA, USA) using the Power SYBR Green PCR 
Master Mix (Thermo). Specificity and efficiency of the PCR reaction was confirmed with melting curve and stand-
ard curve analysis, respectively. Duplicate samples were normalized to glyceraldehyde-3-phosphate dehydroge-
nase (Gapdh) expression. Mean values are expressed with the formula 2−ΔΔCt. Primer sequences were as follows: 
Ctgf forward: ATGCTGTGAGGAGTGGGTGT; Ctgf reverse: GGCCAAATGTGTCTTCCAGT; Tgfb1 for-
ward 5-ACCATCCATGACATGAACC-3; Tgfb1 reverse 5-TCATGTTGGACAACTGCTCC-3; Mmp2 forward: 
5-GCTGATACTGACACTGGTACTG-3; Mmp2 reverse: 5-CACTGT CCGCCAAATAAACC-3; Mmp9 forward: 
5-CTTGAAGTCTCAGAAGGTGGATC-3; Mmp9 reverse: 5-CGCCAGAAGTATTTGTCATGG-3; Timp1 for-
ward: 5-TTTCTG CAACTCGGACCTG-3; Timp1 reverse: 5-ACAGCGTCGAATCCTTTGAG-3; Timp2 forward: 
5-TCGAATTTATCTACACGGCCC-3; Timp2 reverse: 5-GGCACAATAAAG TCACAGAGGG-3; Timp3 forward: 
5-AAGGCAAGATGTACACAGGG-3; Timp3 reverse: 5-TGGAGGTCACAAAGCAAGG-3; Nphs1 (nephrin) 
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forward: 5-GCCTCTTGACCAT CGCTAATG-3; Nphs1 reverse: 5-GACAACCTTCAGTCCCAG TG-3; Nphs2 
(podocin) forward: 5-TCCCTTTTCCATCTGGTTCTG-3; Nphs2 reverse: 5-CTTGTGATAGGTGTCCAGGC-3; 
Gapdh forward: 5-CAATGACCCCTTCATTGA CC-3; Gapdh reverse: 5-CGCCAGTAGACTCCACAACA-3.
Statistics. The statistical analyses were performed with Prism 6 (GraphPad, La Jolla, CA, USA) on a personal 
computer. All the data are presented as mean ± standard deviation (SD). Data were eveluated using two-factorial 
analysis of variance (two-way ANOVA, with ‘diabetes’ and ‘Cinaciguat treatment’ as factors) to detect independ-
ent effects of the factors (p diabetes, p treatment) and significant diabetes × treatment interactions (p interaction). Sidak’s 
multiple comparisons test was performed as post hoc test to evaluate differences between groups. The level of 
significance was set to p < 0.05.
Ethical Approval Statement. All procedures and handling of animals during the investigations were 
reviewed and approved by the local Ethical Committee for Animal Experimentation at Semmelweis University 
and the Directorate of Food Chain Safety and Animal Health of the Pest County Government Office (permission 
number: 22.1/1162/3/2010). The investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No. 85–23, revised 1996) and the European 
Directive 2010/63/EU.
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